Numerai’s Aquestive Therapeutics AQST Stock Holding History

Numerai’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-122,125	Closed	-$789K	–	756
2025 Q4	$789K	Buy	+122,125	New	+$761K	0.1%	297

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Numerai's AQST Position: Q1 2026 in Review

Numerai sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 122,125 shares — an estimated $789K sold.

Numerai first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $789K in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Numerai reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
Numerai sold 122,125 Aquestive Therapeutics shares in Q1 2026, an estimated $789K.
Numerai first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
Numerai's Aquestive Therapeutics position peaked at $789K in Q4 2025.
180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Numerai's 13F filing for Q1 2026, filed 15 May 2026.